Archive


Category: Antimicrobial Resistance

  • ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19

    This week, PhRMA sponsored The Washington Post’s event, Coronavirus: Lessons of the Pandemic, where PhRMA president and CEO Stephen J. Ubl shared crucial lessons learned from the pandemic on how to protect patient access to medicine and ensure the health of our robust supply chain. The event also featured PhRMA board member and Genentech CEO […]

  • US study finds high rates of unneeded antibiotic prescribing

    A study has found that there is still a very high level of inappropriate antibiotic prescribing to patients in the US, particularly to older and Black patients. Sifting through data from around seven billion outpatient visits to doctor’s offices, hospital clinics and emergency departments over a seven-year period, the researchers found that almost three-quarters (74%) […]

  • UK launches its ‘Netflix-style’ payment model for antibiotics

    The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of decline into the category. The Department of Health, NHS England and NICE have completed an evaluation of two new antibiotics – Pfizer’s Zavicefta (ceftazidime/avibactam) and Shionogi’s Fetcroja (cefiderocol) – that […]

  • Sandoz, Ares extend digital alliance on antimicrobial resistance

    Novartis’ generics unit Sandoz has moved on to the next stage of a collaboration with Ares Genetics, which is focusing on the use of artificial intelligence to track antimicrobial resistance (AMR), improve diagnoses and guide the most effective use of antibiotics. Sandoz and Ares – a subsidiary of OpGen – started working together in 2018, […]

  • Pharma-backed antibiotic fund makes first investments

    Two years after it was first proposed and a year after it officially launched, the pharma-backed AMR Action Fund has made its first investments in companies trying to tackle the pressing problem of antibiotic resistance. The Fund – set up as a public-private partnership by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) – […]

  • Venatorx plans new antibiotic filing after phase 3 readout

    Venatorx Pharma has moved a step closer to what has unfortunately become a rare event in pharma – the filing of a new antibiotic designed to tackle the increasing pressing problem of antimicrobial resistance. Armed with positive phase 3 results, Venatorx has said till file for approval its cefepime-taniborbactam combination with the FDA later this […]

  • Boehringer backs AI-powered anti-infective startup ArrePath

    A new company set up to use machine learning to find new anti-infective drugs – ArrePath – has launched onto the scene with $20 million in seed financing from a group of investors including the Boehringer Ingelheim Venture Fund. The Princeton, New Jersey-based startup will use the funding to develop its artificial intelligence and imaging […]

  • ICYMI: New report demonstrates growing global impact of antimicrobial resistance

    New research published in The Lancet shows for the first time the global impact of antimicrobial resistance (AMR), which poses an increasingly serious threat to human health around the world. The study found AMR is directly associated with at least 1.27 million deaths per year, making AMR a leading cause of death globally, higher than […]

  • Antimicrobial resistance caused 4.95m deaths

    That is the title of an editorial by Ramanan Laxminarayan published in The Lancet this week. Part of the rationale from this commentary is a recent study also published this week from the Antimicrobial Resistance Collaborators (2022). Undertaking a systematic review of the mortality impact of antimicrobial resistance (AMR) the authors find: …there were an […]

  • One world, one health: The interconnected web of antimicrobial resistance

    Tackling antimicrobial resistance (AMR) requires a one health approach that joins the dots between the human, animal, and environmental drivers, consequences, and data. AMR threatens to undermine “almost a century of health gains” and marshalling a response to such a problem “requires cooperation at many levels”. That’s according to a newly published report from the […]

  • New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections, but future pipeline remains challenging

    The discovery and introduction of antibiotics in the 1940s transformed modern medicine and enabled tremendous progress in health care and life expectancy. Today, this progress is being threatened by a health crisis on the rise: antimicrobial resistance (AMR). AMR affects at least 3 million Americans and results in 48,000 U.S. deaths annually. The World Bank […]

  • Novartis antibiotic retreat doesn’t stop Sandoz buying GSK drugs

    Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalosporin franchise.  The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which are sold in more than 100 markets […]